All In Biotech

Drug Trial Radar · NCT02728089

Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)

A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection

Last checked: Nov 20, 2026Latest source record: Feb 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Apr 14, 2016

Primary completion

Sep 5, 2017

Study completion Sep 5, 2017

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) for the treatment of complicated urinary tract infection (cUTI) including pyelonephritis (uncomplicated or complicated pyelonephritis and complicated lower urinary tract infection) in Japanese participants. Efficacy will be primarily assessed by microbiological response defined as eradication of the baseline pathogen or pathogens.

Conditions

  • Urinary Tract Infection (UTI)
  • Complicated Urinary Tract Infection
  • Pyelonephritis
  • Uncomplicated Pyelonephritis

Interventions

  • MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)Drug

    MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC)Time frame: Day 14 (14 days post first dose of study drug)
  2. Percentage of Participants Who Report 1 or More Adverse Event (AE)Time frame: Up to 42 days post first dose of study drug
  3. Percentage of Participants Discontinuing Study Drug Due to an AETime frame: Up to 7 days after the first dose of study drug

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.